Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $13.25 USD
Change Today +0.19 / 1.45%
Volume 35.5K
OXFD On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

oxford immunotec global plc (OXFD) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/5/14 - $17.43
52 Week Low
12/12/14 - $10.01
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

oxford immunotec global plc (OXFD) Related Businessweek News

No Related Businessweek News Found

oxford immunotec global plc (OXFD) Details

Oxford Immunotec Global PLC, a diagnostics company, develops and commercializes proprietary tests for the management of immune-regulated conditions in the United States, Europe, Japan, and China. The company develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immunologically controlled diseases. Its solution includes SPOT.TB test, a single-cell based method for identifying latent tuberculosis infection. The company was founded in 2002 and is headquartered in Abingdon, the United Kingdom.

254 Employees
Last Reported Date: 05/6/15
Founded in 2002

oxford immunotec global plc (OXFD) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $406.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $255.0K
Chief Operations Officer
Total Annual Compensation: $268.5K
Chief Commercial Officer
Total Annual Compensation: $311.9K
Compensation as of Fiscal Year 2014.

oxford immunotec global plc (OXFD) Key Developments

Oxford Immunotec Global PLC Announces Enrollment of First Patient in REACT Trial for T-SPOT.CMV

Oxford Immunotec Global PLC announced that the first patient has been enrolled in the REACT study. The REACT study, which focuses on stem cell transplant patients, is the second of two pivotal clinical trials designed to demonstrate the clinical value of Oxford Immunotec's T-SPOT®.CMV test. T-SPOT.CMV test measures the strength of T cell responses to Cytomegalovirus (CMV) to assess susceptibility to CMV infection. CMV disease is a common and serious complication in both solid organ and stem cell transplantation. T-SPOT.CMV test has the potential to assist clinicians with monitoring anti-viral prophylaxis and evaluating patients at risk from CMV disease. The T-SPOT.CMV test leverages Oxford Immunotec's proprietary T-SPOT technology platform.

Oxford Immunotec Global PLC Announces Unaudited Consolidated Earnings Results for First Quarter Ended March 31, 2015; Provides Revenue Guidance for the Second Quarter and Full Year 2015

Oxford Immunotec Global PLC announced unaudited consolidated earnings results for first quarter ended March 31, 2015. For the quarter, the company reported total revenue was $13,801,000 compared to $12,274,000 a year ago. Loss from operations was $6,521,000 compared to $2,939,000 a year ago. Loss before income taxes was $6,264,000 compared to $3,121,000 a year ago. Net loss was $6,311,000 or $0.31 basic and diluted per share compared to $3,153,000 or $0.18 basic and diluted per share a year ago. EBITDA was $5,796,000 compared to $2,735,000 a year ago. Adjusted EBITDA was $5,030,000 compared to $2,406,000 a year ago. The company provided revenue guidance for the second quarter and full year 2015. For the quarter, the company expects to report revenue of between $13.6 million and $14.1 million for the second quarter of 2015. For the full year, the company expects revenue of between $60 and $65 million, representing 21% to 31% year-over-year growth. The company expects revenue to increase 26% to 37% for the year using constant exchange rates.

Oxford Immunotec Global PLC, Annual General Meeting, Jun 09, 2015

Oxford Immunotec Global PLC, Annual General Meeting, Jun 09, 2015., at 11:00 GMT Standard Time. Location: the Innovation Centre, 99 Park Drive. Agenda: To elect James R. Tobin as a class II director for a term to expire at the 2018 annual general meeting of shareholders; to elect Stephen L. Spotts as a class II director for a term to expire at the 2018 annual general meeting of shareholders; to ratify the audit committee’s appointment of Ernst & Young LLP as U.K. statutory auditor and U.S. independent registered public accounting firm for the fiscal year ending December 31, 2015; to re-appoint Ernst & Young LLP as U.K. statutory auditors under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the U.K. statutory accounts and reports are presented; to receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2014; and to receive and approve U.K. statutory annual directors’ remuneration report for the year ended December 31, 2014, which is set forth as Annex A to this proxy statement.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OXFD:US $13.25 USD +0.19

OXFD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OXFD.
View Industry Companies

Industry Analysis


Industry Average

Valuation OXFD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.3x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OXFORD IMMUNOTEC GLOBAL PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at